Vela Pharmaceuticals
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
181 Cherry Valley Rd, Princeton, New Jer...Phone Number
(609) 771-8660Website
www.velapharm.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About Vela Pharmaceuticals
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vela Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Vela Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Vela Pharmaceuticals launches new products
Earning: See what the market has to say on Vela Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Vela Pharmaceuticals
Funding: Get notified immidiatlly once Vela Pharmaceuticals has new funding data
Click to see if Vela Pharmaceuticals had a recent Job posting/layoffs
Check if Vela Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Vela Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at Vela Pharmaceuticals
Find 3 more new buyers
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vela Pharmaceuticals
Vela Pharmaceuticals Inc. (www.velapharm.com), a privately held company, specializes in the "rediscovery" and development of medicines to treat diseases associated with the nervous system. The company uses its extensive drug development expertise to leverage the value of "known" neurotherapeutic molecular assets. Investors include JP Morgan Partner... Read More
